Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

309
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
309
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

581
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
581
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same author

A surviving beta cell subpopulation enriched in patients with T1D.

bioRxiv : the preprint server for biology·2026
Same author

Interlayer Decoupling Growth for Atomically Thin Hybrid Perovskite Ferroelectrics with Giant Rashba Splitting Energy.

Journal of the American Chemical Society·2026
Same author

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design.

Diabetes, obesity & metabolism·2026
Same author

Deep immune profiling of the peripheral blood reveals disease- and sex-associated immune cell signatures in patients with systemic sclerosis.

bioRxiv : the preprint server for biology·2026
Same author

Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same journal

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same journal

Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence.

Diabetes care·2026
Same journal

A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.

Diabetes care·2026
Same journal

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
See all related articles

Related Experiment Video

Updated: Jul 16, 2025

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

2.6K

Hydroxychloroquine in Stage 1 Type 1 Diabetes.

Ingrid Libman1, Polly J Bingley2, Dorothy Becker1

  • 1Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA.

Diabetes Care
|September 14, 2023
PubMed
Summary
This summary is machine-generated.

Hydroxychloroquine did not prevent progression to stage 2 type 1 diabetes (T1D). However, the drug did reduce the development of additional autoantibodies and lower existing autoantibody titers in individuals with stage 1 T1D.

More Related Videos

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.1K
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

16.8K

Related Experiment Videos

Last Updated: Jul 16, 2025

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

2.6K
Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.1K
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

16.8K

Area of Science:

  • Immunology
  • Endocrinology
  • Clinical Trials

Background:

  • Innate immune responses are implicated in the early stages of type 1 diabetes (T1D).
  • Understanding modulators of early T1D progression is crucial for intervention strategies.

Purpose of the Study:

  • To investigate if blocking innate immune cells with hydroxychloroquine could delay or prevent the progression of stage 1 T1D to stage 2.
  • To assess the safety and efficacy of hydroxychloroquine in individuals with early-stage T1D.

Main Methods:

  • A randomized controlled trial involving 273 individuals with stage 1 T1D.
  • Participants were assigned to receive either hydroxychloroquine (5 mg/kg/day, max 400 mg) or a placebo.
  • Progression to stage 2 T1D (defined by multiple autoantibodies and impaired glucose tolerance) was the primary endpoint.

Main Results:

  • The trial was stopped early due to futility; hydroxychloroquine did not delay progression to stage 2 T1D.
  • No safety concerns were reported with hydroxychloroquine treatment.
  • Secondary analyses indicated a transient decrease in glucose AUC and reduced titers of anti-GAD and anti-insulin autoantibodies in the hydroxychloroquine group.

Conclusions:

  • Hydroxychloroquine is ineffective in delaying the progression of type 1 diabetes from stage 1 to stage 2.
  • Hydroxychloroquine treatment demonstrated a beneficial effect on reducing autoantibody acquisition and titers in early T1D.